Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity.

eLife - 4 Mar 2015

Yao Yuwei, Cui Xiaotian, Al-Ramahi Ismael, Sun Xiaoli, Li Bo, Hou Jiapeng, Difiglia Marian, Palacino James, Wu Zhi-Ying, Ma Lixiang, Botas Juan, Lu Boxun

Abstract excerpt

Huntington's disease (HD) represents an important model for neurodegenerative disorders and proteinopathies. It is mainly caused by cytotoxicity of the mutant huntingtin protein (Htt) with an expanded polyQ stretch. While Htt is ubiquitously expressed, HD is characterized by selective neurodegeneration of the striatum. Here we report a striatal-enriched orphan G protein-coupled receptor(GPCR) Gpr52 as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animals, Genetically Modified
Share to Corpus Striatum

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Huntington Disease

Share to Microscopy, Confocal

Share to Motor Activity

Share to Psychomotor Performance

Share to Receptors, G-Protein-Coupled

Share to Serotonin Plasma Membrane Transport Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 25738228
DOI: 10.7554/eLife.05449
PMCID: PMC4372774

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity.PMID 25738228Read ↗

Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.Semantic proximity Read ↗

Huntington's disease and Group I metabotropic glutamate receptors.Semantic proximity Read ↗

Discovery of the First Druggable GPR52 Antagonist to Treat Huntington's Disease.Semantic proximity Read ↗

Huntington’s disease and striatal signalingSemantic proximity Read ↗

The Parkinson's disease-associated GPR37 receptor-mediated cytotoxicity is controlled by its intracellular cysteine-rich domain.Semantic proximity Read ↗

Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's diseaseSemantic proximity Read ↗

Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's diseaseSemantic proximity Read ↗

Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin.Semantic proximity Read ↗

A variant of the autophagic receptor NDP52 counteracts phospho-TAU accumulation and emerges as a protective factor for Alzheimer DiseaseSemantic proximity Read ↗

Striatal cell-type–specific molecular signatures reveal therapeutic targets in a model of dystoniaSemantic proximity Read ↗

A variant of the autophagic receptor NDP52 counteracts phospho-TAU accumulation and emerges as a protective factor for Alzheimer’s diseaseSemantic proximity Read ↗

Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.